Associations between statin adherence level, health care costs, and utilization

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 703-713

  Zhao, Yongming ^a   Zabriski, Steve ^a   Bertram, Carl ^a  

^a Clinical Strategy and Health Outcomes Research Innovation Department Catamaran Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; COST CONTROL; DRUG COST; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; RETROSPECTIVE STUDY; ADOLESCENT; ECONOMICS; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; HYPERLIPIDEMIAS; MIDDLE AGED; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT; CLINICAL EVALUATION; CLINICAL OUTCOME; CORRELATION ANALYSIS; DIABETES MELLITUS; EMERGENCY WARD; GENERALIZED LINEAR MODEL; GOVERNMENT EMPLOYEE; HEALTH INSURANCE; HYPERLIPIDEMIA; ICD-9-CM; LINEAR REGRESSION ANALYSIS; MEDICAL RECORD; MEDICATION POSSESSION RATIO; ODDS RATIO; OUTCOME ASSESSMENT; POISSON DISTRIBUTION; PRESCRIPTION; SCHOOL ADMINISTRATOR; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84903187744     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.703     Document Type: Article

References (25)

1. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-81.
3. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med. 2008;121(1):24-33.
4. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1: CD004816.
5. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37-45.
6. Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med. 2012;125(5):440-46.
7. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-63.
8. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013; Nov. 12 [Epub ahead of print]. Available at: http://circ.ahajournals. org/content/early/2013/11/11/01.cir.0000437738.63853.7a.citation. Accessed April 21, 2014.
9. Evans CD, Eurich DT, Lamb DA, et al. Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manag Care Pharm. 2009;15(6):476-84. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8181.
10. Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462-71.
11. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-79.
12. Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin. 2013;29(3):175-80.
13. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
14. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662-66.
15. Gleason PP, Qiu Y, Starner CI, Ritter S. Statin medication adherence association with hospitalizations or emergency room visits and total cost of care over two years. Poster presented at: Academy of Managed Care Pharmacy 2012 Educational Conference; October 4, 2012; Cincinnati, OH. Available at: http://cdn2.content.compendiumblog.com/uploads/user/e7c690e8-6ff9-102a-ac6d-e4aebca50425/accf0d87-0d14-4aa7- bbf3-193b90c8d68c/File/76aa753764dae59d8a10e1c241bfdffe/4085_b_ fall_2012_amcp_poster_statin_adherence.pdf. Accessed April 21, 2014.
16. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(Spec no.):SP11-19.
17. Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes. Ann Pharmacother. 2011;45(3):342-49.
18. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462-67.
19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-39.
20. Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748-57.
21. Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA. Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. J Clin Psychiatry. 2003;64(10):1201-09.
22. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203-09.
23. Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13(1):87-94.
24. Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011;67(4):407-14.
25. Benner, JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61.